LLYEli Lilly and CompanyRunning, no new patients
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Biliary Tract Cancer · Metastatic Cancer · Advanced Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 309 (final count)
- Started
- May 19, 2016
- Main results expected
- Feb 16, 2018
- Fully finished
- Dec 2026
- Results posted
- Feb 26, 2021
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: Randomization to Progressive Disease or Death from Any Cause (Up To 20 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02711553 · record last updated 2026-07-22 · checked 2026-11-09 15:47 UTC